Retrophin, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.8M
Doctors Paid
6,335
Transactions
18,475
2019 Total
$4.2M
Payment Breakdown by Category
Research$12.9M (81.9%)
Consulting$1.1M (7.0%)
Food & Beverage$164,926 (1.0%)
Travel$139,838 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.9M | 2,722 | 81.9% |
| Grant | $1.2M | 18 | 7.7% |
| Consulting Fee | $1.1M | 504 | 7.0% |
| Food and Beverage | $164,926 | 5,270 | 1.0% |
| Travel and Lodging | $139,838 | 452 | 0.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $133,563 | 76 | 0.8% |
| Education | $96,901 | 9,433 | 0.6% |
Payments by Type
Research
$12.9M
2,722 transactions
General
$2.9M
15,753 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 021FSGS16010 | $1.4M | 13 | 705 |
| Evaluate the QT/QTc Interval Prolongation Potential of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, when Administered to Healthy Subjects: A Thorough Electrocardiographic Study | $1.3M | 0 | 3 |
| A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF SPARSENTAN (RE-021) IN MALE SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT COMPARED TO HEALTHY SUBJECTS | $1.3M | 0 | 21 |
| A Phase 1 Study of the Absorption, Metabolism, and Excretion of RE-024 in Healthy Subjects | $1.2M | 0 | 3 |
| DUET | $1.1M | 0 | 386 |
| 024PKAN15004 | $1.0M | 3 | 436 |
| EVALUATE THE QT/QTC INTERVAL PROLONGATION POTENTIAL OF SPARSENTAN (RE-021) WHEN ADMINISTERED TO HEALTHY SUBJECTS | $655,382 | 0 | 2 |
| 018CTXX15001 | $526,379 | 0 | 284 |
| A Phase 1, Double-blind, Randomized, Placebo-controlled, Sequential, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RE-024 (Phosphopantothenate Replacement Therapy) in Healthy Subjects | $508,009 | 0 | 2 |
| Research Agreement | $499,492 | 0 | 6 |
| 021IGAN17001 | $363,691 | 11 | 293 |
| A RANDOMIZED, BLINDED, PLACEBO- AND ACTIVE-CONTROLLED STUDY TO EVALUATE THE QT/QTC INTERVAL PROLONGATION POTENTIAL OF SPARSENTAN (RE-021) WHEN ADMINISTERED TO HEALTHY SUBJECTS: A THOROUGH ELECTROCARDIOGRAPHIC STUDY | $259,551 | 0 | 2 |
| TQT Study - A Randomized, Double-blind, Placebo- and Active-controlled Study to Evaluate the QT/QTc Interval Prolongation Potential of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, when Administered to Healthy Subjects: A Thorough Electrocardiographic Study | $227,385 | 0 | 2 |
| A PHASE 1 STUDY TO INVESTIGATE THE ABSORPOTION, METABOLISM, AND EXCRETION OF [14]C-SPARSENTAN FOLLOWING A SINGLE ORAL DOSE IN HEALTHY MALE SUBJECTS | $222,106 | 0 | 4 |
| A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-SEQUENCE, 3-PERIOD, PARTIAL CROSSOVER STUDY TO EVALUATE THE INDIVIDUAL EFFECTS OF CYCLOSPORIN AND ITRACONAZOLE ON THE SINGLE-DOSE SAFETY, TOLERABILITY, AND PHARMACOKINETIC PROFILE OF SPARSENTAN IN HEALTHY SUBJECTS | $186,631 | 0 | 2 |
| A SQUENCE RANDOMIZED CROSSOVER STUDY TO DETERMINE THE EFFECTS OF TRANSPORTER OATP1B1, 1B3 INHIBITION BY SPARSENTAN ON PITAVASTATIN PHARMACOKINETICS | $170,830 | 0 | 4 |
| The Replace Registry | $160,792 | 0 | 57 |
| A Food Effect Study with Sparsentan RE-021 | $152,292 | 0 | 1 |
| CTA Site Pmts-CTX Prevalence | $148,838 | 0 | 69 |
| Amendmnt #5 additional analysi | $147,748 | 0 | 2 |
| CTX Prevalence Study | $145,593 | 0 | 136 |
| A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, NONREPLICATE CROSSOVER STUDY TO COMPARE THE BIOAVAILABILITY OF A TABLET FORMULATION OF SPARSENTAN (RE-021) TO A CAPSULE FORMULATION OF SPARSENTAN IN HEALTHY VOLUNTEER SUBJECTS | $120,389 | 0 | 1 |
| A PHASE I, MULTI-DOSE, TWO-PERIOD, OPEN LABEL, SINGLE-SEQUENCE, CROSSOVER STUDY TO EVALUATE CYP3A4 AND CYP2B6 INDUCTION BY SPARSENTAN | $120,389 | 0 | 1 |
| CROSSOVER STUDY TO EVALUATE THE INDIVIDUAL EFFECTS OF CYCLOSPORIN AND ITRACONAZOLE ON THE SINGLE-DOSE SAFETY, TOLERABILITY, AND PHARMACOKINETIC PROFILE OF SPARSENTAN IN HEALTHY SUBJECTS | $120,367 | 0 | 1 |
| FORT Study | $90,682 | 11 | 14 |
| CROSSOVER STUDY TO COMPARE THE BIOAVAILABILITY OF A TABLET FORMULATION OF SPARSENTAN (RE-021) TO A CAPSULE FORMULATION OF SPA | $87,254 | 0 | 2 |
| Crossover Study to Determine the Effects of P-gp Inhibition on the Pharmacokinetics of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Healthy Subjects | $69,148 | 0 | 2 |
| CTX Prevalence 018CTXX15001 | $56,663 | 0 | 34 |
| Study of Cholic Acid Capsules | $52,524 | 0 | 2 |
| Protocol # RET-D-001 | $50,124 | 7 | 34 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Unknown Provider | — | — | $121,793 | $0 |
| Sam Teichman, Md, MD | Cardiovascular Disease | Oakland, CA | $116,064 | $0 |
| Dr. Patrick Mufarrij, Md, MD | Urology | Washington, DC | $56,954 | $0 |
| Glenn Preminger, M.d, M.D | Urology | Durham, NC | $53,030 | $0 |
| Robert Nadler, Md, MD | Urology | Springfield, IL | $49,616 | $0 |
| Dr. David Goldfarb, M.d, M.D | Nephrology | New York, NY | $44,540 | $0 |
| Dr. Derek Larson, M.d, M.D | Nephrology | Creve Coeur, MO | $35,860 | $0 |
| Mr. Mehul Dixit, Md Dm, MD DM | Pediatric Nephrology | Jackson, MS | $33,797 | $0 |
| Dr. Roger Sur, M.d, M.D | Urology | San Diego, CA | $27,578 | $0 |
| Dr. Ernst Schaefer, M.d, M.D | Endocrinology, Diabetes & Metabolism | Boston, MA | $27,491 | $0 |
| Robert Steiner, Md, MD | Clinical Biochemical Genetics | Madison, WI | $27,227 | $0 |
| Anna Zisman | Internal Medicine | Chicago, IL | $27,015 | $0 |
| Unknown Provider | — | — | $24,200 | $0 |
| Dr. Aleksandar Videnovic, M.d, M.D | Neurology | Boston, MA | $23,556 | $0 |
| Charina Ramirez, Md, MD | Pediatrics | Dallas, TX | $23,205 | $0 |
| Jorge Kusnir, M.d, M.D | Nephrology | Orlando, FL | $23,133 | $0 |
| Dr. Justin Friedlander, M.d, M.D | Urology | Philadelphia, PA | $22,443 | $0 |
| Dr. Ryan Himes, M.d, M.D | Pediatrics | New Orleans, LA | $21,281 | $0 |
| Dr. Peter Nelson, M.d, M.D | Nephrology | Seattle, WA | $20,000 | $0 |
| Dr. Migvis Monduy, M.d, M.D | Neurology with Special Qualifications in Child Neurology | Miami, FL | $19,477 | $0 |
| Gregory Enns, M.d, M.D | Medical Biochemical Genetics | Palo Alto, CA | $17,963 | $0 |
| Bruce Baker, Md, MD | Nephrology | Lewisville, TX | $16,739 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $15,450 | $0 |
| Jonathan Hogan, Md, MD | Nephrology | Philadelphia, PA | $15,225 | $0 |
| Dr. Joel Baranski, M.d, M.D | Nephrology | San Diego, CA | $14,922 | $0 |
Ad
Top Products
- (810) Chenodal $1.7M
- (820) Cholbam $745,631
Associated Products (3)
- (810) Chenodal $2.3M
- (815) Thiola $1.0M
- (820) Cholbam $1.0M
Payment Categories
- Food & Beverage $164,926
- Consulting $1.1M
- Travel & Lodging $139,838
- Research $12.9M
About Retrophin, Inc.
Retrophin, Inc. has made $15.8M in payments to 6,335 healthcare providers, recorded across 18,475 transactions in the CMS Open Payments database. In 2019, the company paid $4.2M. The top product by payment volume is (810) Chenodal ($1.7M).
Payments were distributed across 128 medical specialties. The top specialty by payment amount is Nephrology ($360,448 to 785 doctors).
Payment categories include: Food & Beverage ($164,926), Consulting ($1.1M), Research ($12.9M), Travel & Lodging ($139,838).
Retrophin, Inc. is associated with 3 products in the CMS Open Payments database.